Coeptis Therapeutics' Transformative Z Squared Merger Nears Close, Pivoting to Crypto Infrastructure
Summary
The transformative merger between Coeptis Therapeutics Holdings and Z Squared Inc. is in its final stages, with closing described as imminent. Shareholders approved all merger proposals on January 30, and the SEC declared the S-4 registration effective for the $835 million transaction. Upon closing, Coeptis shareholders will retain 21% of the combined entity, which will operate as Z Squared, a Nasdaq-listed digital infrastructure company focused on Dogecoin and Litecoin network validation. Simultaneously, Coeptis will spin out its biopharmaceutical operations into a new independent entity, Gear Therapeutics, distributing shares pro-rata to existing shareholders. This event fundamentally reshapes Coeptis's business model, transitioning it from a biotech company to a crypto infrastructure operator while preserving biotech exposure through the spin-out, pending final Nasdaq listing approval. Traders should monitor for the official closing announcement and the new ticker launch.
At the time of this announcement, COEP was trading at $13.75 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $76M. The 52-week trading range was $6.26 to $21.41. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Acceswire.